Mounjaro and Sleep Apnoea: What Clinical Trials Actually Found

What SURMOUNT-OSA found, and why the numbers matter

The SURMOUNT-OSA trial, published in the New England Journal of Medicine, enrolled adults with moderate-to-severe obstructive sleep apnoea and obesity. It ran two parallel groups: one for people not using CPAP therapy, one for those who were. In the non-CPAP group, participants on tirzepatide saw their apnoea-hypopnoea index fall by around 25 events per hour on average, compared with roughly four events per hour on placebo. That is approximately a 60% reduction. The CPAP group produced a similar proportional result. Crucially, a meaningful proportion of participants crossed below 15 events per hour (the conventional clinical threshold that separates moderate disease from mild) and some moved into remission criteria entirely.

These are not the kind of numbers sleep medicine researchers expected from a weight-loss medicine alone. The scale of the improvement tracked closely with the degree of weight lost, which points to the mechanism being largely, though perhaps not exclusively, about fat distribution in the upper airway. You can read the deeper mechanistic discussion on how tirzepatide helps sleep apnoea if that is where your questions are heading.

The trial results informed the US regulatory approval of tirzepatide for sleep apnoea in 2024, and the full prescribing information is available if you want to read the tirzepatide USPI documentation that underpins that approval. The UK licensing picture is a separate matter (explored below) and is the question our clinical team fields most often in this area.

The UK licensing position right now

As of summer 2026, Mounjaro holds a UK licence for weight management and for type 2 diabetes. It does not yet carry a specific UK indication for obstructive sleep apnoea as a standalone condition. That does not mean the evidence is absent; it means the regulatory process moves on its own timeline, and the MHRA makes UK approval decisions independently of other regulators. A fuller account of where that process stands is on the expected UK approval timeline page.

What does matter for people with sleep apnoea right now is that the condition appears on the list of weight-related comorbidities in the Mounjaro SmPC. That means obstructive sleep apnoea can lower your eligibility BMI threshold from 30 to 27 for private treatment. If your BMI sits in the 27–29.9 range and you have a documented diagnosis, that is worth knowing. The eligibility picture is covered fully on the Mounjaro overview page, including what a prescriber looks at beyond the BMI number itself.

If cost context is relevant to your decision, the weight-loss treatments page sets out what a private prescription includes (consultation, clinical review, delivery and aftercare) in one transparent figure.

Why weight loss improves obstructive sleep apnoea, the short version

Fat deposits around the neck and upper airway narrow the space through which air travels during sleep. When throat muscles relax at night, that narrowed passage collapses intermittently, causing the repeated pauses in breathing that define OSA. Weight loss reduces the soft-tissue bulk pressing on the airway. It can also improve the neuromuscular tone of the upper airway muscles over time, though this is less well characterised than the anatomical effect.

Tirzepatide's mechanism (slowing gastric emptying, reducing appetite through GIP and GLP-1 receptor activation, and driving substantial fat loss) addresses exactly this pathway. The NHS patient information on tirzepatide notes the medicine's role in weight management alongside a reduced-calorie diet and increased activity, which remain the recommended accompaniment to pharmacological treatment.

It is worth being honest: some people with OSA have a significant neuromuscular component to their disease, and weight loss alone (however substantial) does not resolve their condition. CPAP or other airway interventions may still be needed alongside any weight-management treatment. A prescriber who knows your full history is the right person to assess that picture; no weight-loss medicine replaces a sleep study or an ENT assessment.

What this means for someone considering Mounjaro

If you have obstructive sleep apnoea and are thinking about Mounjaro, you are probably frustrated that the path to getting it is less clear than the evidence seems to warrant. That is a reasonable frustration. The clinical data are genuinely compelling, and the regulatory position has not yet caught up, at least not in the UK.

What a prescriber at a service like ours will do is review your BMI, your documented comorbidities including sleep apnoea, your current medications, and your wider health history. Obstructive sleep apnoea as a weight-related condition is a legitimate part of that clinical picture under the existing Mounjaro licence. The process at our GPhC-registered pharmacy starts with a free consultation, reviewed the same day by a named Independent Prescriber, not by an automated system.

The question of whether Mounjaro is right for you specifically is one our clinical team can work through properly. More background on Mounjaro and sleep apnoea suitability covers individual factors in more depth, and the sleep apnoea and Mounjaro topic page pulls together the wider clinical picture if you want a broader read before deciding.